2017 Fiscal Year Final Research Report
A study of bone metabolism using an anti RANKL antibody-treated mouse model.
| Project/Area Number |
16K20655
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthodontics/Pediatric dentistry
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 抗RANKL抗体 / デノスマブ / 破骨細胞 |
|---|
| Outline of Final Research Achievements |
An anti-bone-resorptive drug Denosumab, an anti-RANKL antibody, is used to treat adults' bone disease because of its inhibitory effect of osteoclast differentiation. However, the precise effect of anti-RANKL antibody in younger patients are unknown. In the present study, we analyzed the effect of anti-RANKL antibody on growth and bone metabolism in young mice. Newborn mice exposed to the antibody in utero were normally born, but died within 24 h after birth. Mice, which were treated with anti-RANKL antibody at 1-week-old, showed decreased osteoclastogenesis and increased bone mass at the age of 2 weeks. However, at the age of 8 weeks, mice showed normal body length, body weight and tooth development. These results suggest that an anti-RANKL antibody is safety and efficacious in young patients.
|
| Free Research Field |
歯科薬理学
|
